Tool | Page 41 of 46 | SpiritIndia.com

Breast Cancer :: Breast cancer gene offers promising target for drugs

Researchers at UT Southwestern Medical Center have for the first time described how multiple copies of a gene are responsible for metastases in early-stage breast cancer and poor prognosis for patients. In a study published in this week’s issue of the Proceedings of the National Academy of Sciences, the gene, called uPAR, offers a promising target for therapeutic drugs to stop or slow the progression of the disease and could serve as a screening tool for assessing which types of drugs a patient will respond to.

Anorexia eating disorder in British women for hour glass figure

Anorexia – an eating disorder characterized by low body weight (less than 85 percent of normal weight for height and age), a thin body image, and an intense fear of gaining weight. A startling report has revealed that one in hundred British women suffer from some form of eating disorder like anorexia, bulimia, etc.

Health :: ORIDIS Biomed Licenses NIH’s Proprietary Tissue Micro-Array Technology

ORIDIS Biomed, a biopharmaceutical company announced that it has entered into a license agreement with the National Institutes of Health (NIH) for the worldwide commercial use of NIH’s proprietary Tissue Micro-Array (TMA) technology.

ADHD :: Daytrana, methylphenidate transdermal system provides individualized ADHD symptom management

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch, DAYTRANA tm (methylphenidate transdermal system), has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when the ADHD patch is taken off earlier than the recommended nine hours. The ability to remove the patch earlier than the recommended nine-hour wear time allows physicians the opportunity to manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping. These phase IIIb clinical trial results were reported today at a major scientific and educational meeting of child and adolescent psychiatrists in San Diego, Calif.

ADHD :: Lisdexamfetamine dimesylate in ADHD phase 3 data presented

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that their investigational ADHD treatment, lisdexamfetamine dimesylate (also known as NRP104 or LDX), yielded a 60 percent improvement in the primary rating scale scores for symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 years who received six months of treatment in an open-label phase III study. Results also demonstrated that at 6 months, 95 percent of children taking lisdexamfetamine dimesylate (NRP104/LDX) produced a “much improved” or “very much improved” rating on the Clinical Global Impressions ? Improvement score. These results were presented last weekend at a national meeting of child and adolescent psychiatrists.

Osteosarcoma :: IDM Pharma’s Junovan, mifamurtide in the treatment of osteosarcoma

IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted an electronic New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Junovan(TM) (mifamurtide for injection), requesting approval for its use in the treatment of newly diagnosed resectable high grade osteosarcoma patients following surgical resection in combination with multiple agent chemotherapy.

Cancer :: Gene activation test for right cancer chemotherapy treatment

A new test could now be able to improve doctors’ ability to recommend the right type of cancer treatment for their patients. According to the researchers, the test, which has been developed by Anil Potti at the Duke Institute for Genome Sciences and Policy in Durham, North Carolina, is 80% accurate in predicting the right chemotherapy to cure each person’s cancer.

Imaging :: Philips streamlines cath lab care and management

Royal Philips (NYSE: PHG, AEX: PHI) will showcase innovative cardiac solutions designed to streamline workflow and facilitate advanced information management at Cardiovascular Research Foundation?s (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.Shown for the first time ever in the U.S., the pre-release of the Philips Xcelera 2.1 Cardiovascular Information Solution is one of the key components to Philips integrated catheterization (cath) lab, which includes physiomonitoring, reporting and cardiovascular X-ray technologies to improve patient care and lab management.

MRI :: HYPER-CEST MRI breaks new ground in molecular imaging

Researchers with the U.S. Department of Energy’s Lawrence Berkeley National Laboratory and the University of California at Berkeley have developed a new technique for Magnetic Resonance Imaging that allows detection of signals from molecules present at 10,000 times lower concentrations than conventional MRI techniques. Called HYPER-CEST, this technique could become a valuable tool for medical diagnosis, including the early detection of cancer.

Eating Disorders :: Hair reveals eating disorders – Utah’s Brigham Young University

US scientists have come up with a new way to determine whether someone is suffering from an eating disorder – examining their hair. A study released by researchers from Utah’s Brigham Young University found that examining carbon and nitrogen in the proteins of hair could reveal information about a person’s day-to-day nutrition.